BIO BLAST PHARMA LTD's ticker is ORPN and the CUSIP is M20156101. A total of 15 filers reported holding BIO BLAST PHARMA LTD in Q3 2016. The put-call ratio across all filers is - and the average weighting 0.1%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q1 2017 | $167,000 | -75.7% | 219,905 | -66.7% | 0.01% | -77.5% |
| Q4 2016 | $687,000 | -49.3% | 660,157 | -15.8% | 0.04% | -21.6% |
| Q3 2016 | $1,356,000 | +2.1% | 784,057 | -5.6% | 0.05% | -26.1% |
| Q2 2016 | $1,328,000 | -53.0% | 830,253 | -26.8% | 0.07% | -51.1% |
| Q1 2016 | $2,824,000 | – | 1,133,937 | – | 0.14% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| Knoll Capital Management, LLC | 338,110 | $2,458,000 | 0.96% |
| DSC Advisors, L.P. | 114,602 | $833,000 | 0.42% |
| SPHERA FUNDS MANAGEMENT LTD. | 150,000 | $1,091,000 | 0.14% |
| Visium Asset Management, LP | 627,000 | $4,558,000 | 0.07% |
| Ground Swell Capital, LLC | 689 | $5,000 | 0.01% |
| Soros Fund Management | 71,254 | $518,000 | 0.00% |
| MORGAN STANLEY | 24 | $0 | 0.00% |
| Tower Research Capital LLC (TRC) | 300 | $2,000 | 0.00% |
| UBS AG | 498 | $4,000 | 0.00% |